New England Journal of Medicine
May 21, 2020 Vol. 382 No. 21
http://www.nejm.org/toc/nejm/medical-journal

Original Article
Remdesivir for Covid-19 — Preliminary Report
J.H. Beigel and Others
Conclusions
Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705. opens in new tab.)